Trader consensus at 95.5% implied probability of no FDA-approved hantavirus vaccine by year-end 2026 reflects the early pipeline status of all candidates. Leading efforts, including Moderna–Korea University mRNA constructs and UTMB single-dose mRNA platforms targeting Andes virus, remain in preclinical or pre-Phase 1 stages following promising rodent immunogenicity data from 2025–2026. DNA and subunit candidates have completed only Phase 1 safety trials, with no Phase 3 efficacy studies active. Standard regulatory timelines for rare pathogens require multi-year pivotal testing absent extraordinary funding surges. Recent MV Hondius outbreak visibility has prompted additional grants and monitoring but has not altered development schedules or triggered emergency-use pathways. A sudden large-scale outbreak or accelerated authorization could theoretically compress timelines, though current low incidence and surveillance data make such shifts improbable before December 31.